Finally, although these models have demonstrated good performance in patients within the PSA “gray zone”, the negative predictive values vary substantially across studies, suggesting that predictive accuracy may fluctuate in populations with lower PSA levels or reduced tumor burden (9). The gene discussed is KLK3; the disease is neoplasm.